Neutrophil to Lymphocyte Ratio and Clozapine Response in Treatment Resistant Schizophrenia: An Individual Participant Data Meta-Analysis

Authors:

Abstract
Background: Treatment-resistant schizophrenia (TRS) affects one in three people with schizophrenia. Clozapine remains the only approved treatment, yet its mechanism of action is poorly understood. Converging evidence implicates immune dysregulation in TRS and suggests clozapine exerts unique immunomodulatory effects, but large-scale clinical data linking immune biomarkers – such as the neutrophil-to-lymphocyte ratio (NLR) – to clozapine response are lacking. We tested whether higher baseline NLR predicts clozapine response and whether NLR normalizes with effective treatment.Methods: We collected individual participant data – through systematic review, data repositories, and expert consultation – to conduct a meta-analysis of clozapine trials (8–24 weeks) in adults with TRS. All datasets underwent a standardized analytic pipeline. Primary analyses were logistic regression of baseline NLR predicting response (≥20% symptom improvement) and correlation between change in NLR and change in symptoms. Study-level estimates were pooled using fixed-effects meta-analysis. Meta-regressions examined sex, age, race, baseline severity, and baseline NLR. People with lived experience were involved in the interpretation of the results.Findings: Ten trials contributed 593 participants (236 [39·8%] female; mean age 37·5 years [SD 3·8]; 281 [47·4%] African ancestry). Mean baseline PANSS total was 90·1 (SD 16·2), baseline NLR 1·66 (SD 0·34), and pooled response rate 48·1%. Higher baseline NLR predicted clozapine response (OR=1·26; 95% CI 1·02–1·55; p=0·03; I2=0%). Female sex was independently associated with response (OR=1·66; 95% CI 1·14–2·41; p=0·008). NLR decreased as symptoms improved (r=−0·11; 95% CI −0·19 to −0·03; p=0·01; I2=0%). No study-level covariates moderated either association and there was no evidence of publication bias.Interpretation: Clozapine may exert its antipsychotic effects in TRS partly through normalisation of a heightened inflammatory state. Pre-treatment NLR, already routinely available from mandatory baseline blood work, could support earlier and more targeted clozapine initiation and inform development of novel anti-inflammatory strategies for TRS.PanelResearch in contextEvidence before this studyConverging evidence suggests that treatment resistant schizophrenia (TRS) is characterized by immune dysregulation and altered neuroimmune activity. Clozapine is the only drug indicated for TRS, and it is associated with unique immune mediated off target effects (e.g., benign fever, myocarditis…) and animal model data indicating immunomodulatory effects. Small studies suggest that immune effects may mediate clozapine unique antipsychotic properties in TRS, but large-scale clinical data is lacking.Added value of this studyIn this large-scale individual participant data meta-analysis we show that a higher inflammation state indicated by greater neutrophil to lymphocyte ratio (NLR) is associated with greater odds of responding to clozapine and that as symptoms improve the NLR normalizes.